More on Pseudohypocalcemia and Gadolinium-Enhanced MRI

Publisher Website
Google Scholar
Abstract
In their letter to the editor, Doorenbos et al. (Aug. 21 issue)1 describe seven cases of severe pseudohypocalcemia after gadolinium-enhanced magnetic resonance angiography with the use of gadodiamide. Their report represents an important warning to all physicians, especially since such laboratory interference can occur after any gadodiamide-enhanced magnetic resonance imaging (MRI) examination. Gadodiamide and gadoversetamide are the two gadolinium chelates known to interfere with the colorimetric methods of measuring serum calcium used in most hospitals.2-5 However, five other gadolinium contrast agents do not show this interference: gadopentetate dimeglumine (Magnevist) and gadoteridol (ProHance), which are widely used in the United States, and gadobenate dimeglumine (MultiHance), gadobutrol (Gadovist), and gadoterate meglumine (Dotarem), which are available in Europe and selected countries elsewhere.